Drugs / GKL-006Allo Injection
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07704515 | Aug 2026 → Sep 2028 expected | — | Beijing Gene Key Life Technology Co., Ltd | Not yet recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | GKL-006Allo Injection | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07704515 ↗ |
| Modality | Cell therapy | “GKL-006Allo Injection is an allogeneic invariant natural killer T (iNKT) cell therapy.” NCT07704515 ↗ |